Please login to the form below

Not currently logged in
Email:
Password:

haemophilia A

This page shows the latest haemophilia A news and features for those working in and with pharma, biotech and healthcare.

First blood to Roche in Hemlibra patent fight with Shire

First blood to Roche in Hemlibra patent fight with Shire

Hemlibra has been approved in the US, Europe and Japan to prevent or reduce the frequency of bleeding episodes in patients with haemophilia A who have developed inhibitors to Factor VIII. ... The haemophilia A with inhibitors category is currently

Latest news

  • Roche wins European approval for bleeding disorder treatment Hemlibra Roche wins European approval for bleeding disorder treatment Hemlibra

    The rare bleeding disorder treatment, which is cleared in the EU for routine prophylaxis of bleeding episodes in people with haemophilia A, becomes the first new medicine in over 20 years ... haemophilia A with inhibitors a new medicine for the first

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Novartis’unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab). ... Co’s Keytruda (pembrolizumab), and Hemlibra which has bagged US

  • Roche wins CHMP backing for Hemlibra Roche wins CHMP backing for Hemlibra

    Roche wins CHMP backing for Hemlibra. Haemophilia A treatment on course for European approval. ... If Hemlibra is passed it will be the first new medicine to treat haemophilia A with inhibitors in Europe in over 20 years.

  • Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

    Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... thalassaemia and sickle cell

  • Shire wins FDA approval for haemophilia dosing software Shire wins FDA approval for haemophilia dosing software

    Shire wins FDA approval for haemophilia dosing software. The web-based myPKFiT supports the pharma firm's Advate treatment. ... US regulators have approved Shire’s new web-based dosing software for its recombinant Factor VIII haemophilia A treatment

More from news
Approximately 13 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... Strategically caplacizumab represented a good

  • The good, the bad and the ugly The good, the bad and the ugly

    However, investors fear that challenges in the $11bn haemophilia market could lead to a slump in the haemophilia business it inherited through the Baxalta purchase. ... These two players will have a comfortable advantage over their nearest rival - Roche (

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

  • Deal Watch August 2016 Deal Watch August 2016

    Sanofi sought to take control of Medivation's board using a paper vote. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV vector and the academic

  • A rare opportunity A rare opportunity

    Sobi, handing Sobi commercialisation control over the haemophilia A treatment just four months after it received EU approval. ... Elocta is an excellent product - it's the first extended half-life treatment for haemophilia A and the first real advance in

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Freeline comprises some of the world’s leading experts in gene therapy, haemophilia and other debilitating disorders and I look forward to working closely with them to demonstrate the potential of ... She has also worked at Novo Nordisk as senir vice

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Living with haemophilia – the power of knowledge

    Haemophilia is a genetic disorder that prevents blood from clotting [1]. It is a predominantly male disorder, with haemophilia A occurring in 1 in 5, 000 live male births [1]. ... Untreated, haemophilia can be extremely debilitating, making everyday

  • Attracting doctors to low-demand specialties: A role for industry?

    Haemophilia. One of the specialties in which Porterhouse has worked for many years is haemophilia, a disease that finds itself in a somewhat anomalous position. ... such as leukaemias, lymphomas and myelomas, while haemophilia warrants just one or two

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics